Every Form 4 that Biomerica Inc (BMRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRA filings page.
BIOMERICA INC (BMRA) director Gary M. Huff reported purchasing additional common stock. On August 20, 2026, he acquired 31,250 shares of common stock at $1.60 per share, in a private placement by Biomerica pursuant to a Securities Purchase Agreement dated August 20, 2026. Following this transaction, he directly holds 51,250 shares of Biomerica common stock.
BIOMERICA INC (BMRA) director David Moatazedi reported purchasing common stock in a company financing. On August 26, 2026, he acquired 10,000 shares of Biomerica common stock at $1.60 per share in a private placement by Biomerica under a Securities Purchase Agreement dated August 20, 2026. Following this transaction, he directly holds 40,625 shares of Biomerica common stock.
BIOMERICA INC (BMRA) director Eric Chin reported buying common stock in a company financing. On August 26, 2026, he purchased 6,250 shares of Biomerica common stock at $1.60 per share in a private placement by Biomerica under a Securities Purchase Agreement dated August 20, 2026. Following this transaction, he directly holds 38,750 shares of Biomerica common stock.
BIOMERICA INC (BMRA) director and Executive Vice Chairman Allen Barbieri reported a purchase of 20,000 shares of common stock on August 26, 2026. The shares were acquired at $1.60 per share in a private placement by Biomerica under a Securities Purchase Agreement dated August 20, 2026. Following this transaction, Barbieri directly holds 73,542 common shares.
BIOMERICA INC (BMRA) reported an insider share purchase by Chief Executive Officer and director Zackary S. Irani. On August 26, 2026, he purchased 31,250 shares of Biomerica common stock at $1.60 per share in a private placement conducted by Biomerica.
The transaction was made pursuant to a Securities Purchase Agreement dated August 20, 2026 involving certain institutional and individual investors, including B. Riley Principal Capital, LLC and certain members of Biomerica’s board and executive officers. Following this transaction, Irani directly holds 242,570 common shares.
Biomerica director Eric Chin reported an equity award of 22,500 shares of common stock on December 12, 2025. The grant was issued at $0 per share as restricted stock under the company’s 2024 Stock Incentive Plan. Following this award, he beneficially owns 32,500 common shares directly. The restricted stock will vest in full on the one-year anniversary of December 12, 2025, if he remains in continuous service, with potential accelerated vesting in certain events, including specified changes of control.